Peter Greene and Peter Naismith were quoted in Financial News discussing the continued appeal of co-mingled funds among US hedge fund founders and the fundraising challenges facing emerging managers.

Discussing launch structures and the use of separately managed accounts (SMAs), Peter Greene said, “Looking back over the past few years and considering the pipeline for 2027, we estimate that approximately 50% of our emerging manager clients launch with only a co-mingled fund, 30% launch with a co-mingled fund and at least one SMA, and 20% launch with only one or more SMAs.”

Peter Naismith noted that, while technology has reduced operational barriers to launching hedge funds, attracting capital remains challenging. “What has not become easier is raising capital. Allocators are concentrating their relationships, with a disproportionate share of inflows going to the largest multi-strategy platforms and the most well-pedigreed emerging managers,” he said.

He also emphasized the continued importance of a new manager’s track record and seed or anchor relationships.

Read the full article in Financial News: “Why US hedge fund founders aren’t giving up on co-mingled funds.”

In a recent Inside Health Policy article, Kyle Faget discusses what FDA’s status report on its mifepristone safety assessment could mean for the Louisiana v. FDA case, which seeks to reinstate in-person requirements for the drug and could upend telehealth access to abortion pills.

Kyle explained that FDA would need to find safety signals to justify rolling back the current REMS to in-office dispensing, and that the agency will face pressure from both sides of the abortion debate whatever the review concludes. She also questioned whether the incoming FDA commissioner will push to speed up the process as political pressure builds. If the review finds no new safety signals and the prescribing requirements stay the same, Kyle noted, the case would turn on a larger question: what a single state can do to challenge FDA’s regulatory framework with nationwide effect.

In a recent Modern Healthcare article, Tony Maida discusses HHS’s formal delegation of permissive exclusion authority to CMS, a power that had previously been held solely by the HHS Office of Inspector General. Tony noted that the notice leaves open questions about what happens when CMS and the OIG disagree on an exclusion decision, and whether CMS will use this authority alongside its other enforcement tools.

McDermott Will & Schulte senior consultant Lisa Göransson spoke with S&P Global Market Intelligence about growing private equity investment in Asia-Pacific health care facilities, with investment reaching $1.91 billion through August 2026, surpassing the $990 million recorded for the whole of 2025.

Lisa highlighted increasing investor interest in established hospital and specialist-care platforms that offer opportunities for expansion.

“Demand for health care is growing, while hospital and specialist-care groups increasingly offer investors a platform they can expand through new facilities, services and acquisitions,” she noted.

The article also explores the role of India in driving regional investment activity, alongside emerging opportunities in specialist care and other Asia-Pacific markets.

Read the full S&P Global Market Intelligence article >>

Subscription may be required.

A McDermott team led by Doug Carsten, Adam Burrowbridge, and Art Dykhuis was recognized in Law.com’s Litigator of the Week roundup for securing an important patent ruling for United Therapeutics Corp. in its litigation against Liquidia Technologies Inc.

After a four-day bench trial in the District of Delaware, the court found that Liquidia’s product, Yutrepia, infringed the patent-in-suit and rejected Liquidia’s challenges to two key claims of a United Therapeutics patent covering treatments for pulmonary hypertension associated with interstitial lung disease. McDermott worked on the matter alongside a team from Goodwin Procter.

Partner Andrea Giaretta, Counsel Nadia Cuppini and Associate Marco Colombo authored an article for International Financial Law Review (IFLR) examining how the implementation of AIFMD II is reshaping Italy’s private credit market and the implications for alternative investment fund (AIF) managers.

The authors explore how the new framework simplifies market access for EU funds while introducing considerations around fund classification, loan origination, leverage, liquidity and credit risk management. They also highlight areas requiring further regulatory clarification as Italy prepares to finalise its implementing measures.

Read the full IFLR article >>

Subscription may be required.

McDermott Will & Schulte Italy Managing Partner Vincenzo Giannantonio spoke with Milano Finanza about the Firm’s growth strategy in Italy, recent expansion and the changing legal market.

Vincenzo highlighted McDermott’s ambitions to become a leader in the mid-market and private capital sectors, supported by its integrated international platform and continued investment in talent.

He also discussed the impact of artificial intelligence on the legal profession, increasing consolidation across the market and the continued importance of trusted client relationships.

The interview forms part of Milano Finanza’s coverage of lateral hiring activity across Italian law firms, which also highlighted the arrival of Counsel Andrea D’Ettorre at McDermott.

Read the full Milano Finanza article >>

McDermott Will & Schulte partner Milo Molfa spoke with LegalCommunity about the K2 arbitration involving Maire Tecnimont and EuroChem, following a significant ruling in a dispute arising from the suspension of an industrial project in Russia after the invasion of Ukraine.

Speaking alongside Maire Group General Counsel Fabio Fagioli, Milo discussed the legal strategy behind the four-year dispute, which saw a London-seated arbitral tribunal uphold the legitimacy of the contract suspension and award approximately €260 million in costs to Tecnimont and its subsidiary.

The interview explores the complexities of international sanctions, parallel proceedings across multiple jurisdictions and the importance of collaboration between in-house and external legal teams.

Read the full LegalCommunity article >>